Key result
Human platelets generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin supplementation (75 mg/day) or in vitro COX-1 blockade.
Population
Human platelets
Comparison
Agonist activation, in vivo aspirin… vs Unactivated platelets / no aspirin or COX-1…
Design
Preclinical
Authors
Loading...
May inform aspirin's effects on platelet lipid mediators; leaves open clinical relevance in thrombosis pending human validation.
Human platelets acutely generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin.
Aldrovandi et al. (2013) studied this question. Aspirin supplementation or COX-1 blockade was evaluated on Generation of prostaglandin-esterified phospholipids. Human platelets generate prostaglandin-esterified phospholipids via COX-1 upon activation, a process that is inhibited by low-dose aspirin supplementation (75 mg/day) or in vitro COX-1 blockade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: